{"id":50603,"date":"2025-12-13T21:57:56","date_gmt":"2025-12-13T13:57:56","guid":{"rendered":"https:\/\/flcube.com\/?p=50603"},"modified":"2025-12-13T21:57:57","modified_gmt":"2025-12-13T13:57:57","slug":"insilico-licenses-ai-designed-ism4808-phd-inhibitor-to-taigen-in-two-digit-million-dollar-greater-china-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50603","title":{"rendered":"Insilico Licenses AI\u2011Designed ISM4808 PHD Inhibitor to TaiGen in Two\u2011Digit Million Dollar Greater China Deal"},"content":{"rendered":"\n

Insilico Medicine<\/strong> and TaiGen Biotechnology<\/strong> (including its Beijing subsidiary TaiGen Biopharmaceuticals) announced an exclusive pipeline out\u2011licensing collaboration for ISM4808<\/strong>, a potential best\u2011in\u2011class oral PHD inhibitor<\/strong> developed via Insilico\u2019s Chemistry42 AI engine<\/strong>. TaiGen gains exclusive rights for development, commercialization, and sub\u2011licensing in Greater China<\/strong> (Mainland China, Hong Kong, Macau, Taiwan). Insilico is eligible for upfront, development and sales\u2011based milestone payments<\/strong>, plus tiered royalties<\/strong>, with total deal value reaching the two\u2011digit million dollar range<\/strong>.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Component<\/th>Details<\/th><\/tr><\/thead>
Asset Licensed<\/strong><\/td>ISM4808 (oral PHD inhibitor) + related forms\/structures<\/td><\/tr>
Territory<\/strong><\/td>Greater China (Mainland, Hong Kong, Macau, Taiwan)<\/td><\/tr>
Rights<\/strong><\/td>Exclusive development, commercialization, and sub\u2011licensing<\/td><\/tr>
Upfront Payment<\/strong><\/td>One\u2011time upfront (undisclosed)<\/td><\/tr>
Milestone Payments<\/strong><\/td>Development and sales\u2011based milestones<\/td><\/tr>
Total Deal Value<\/strong><\/td>Two\u2011digit million USD<\/strong> (estimated $30\u201199\u202fM)<\/td><\/tr>
Royalties<\/strong><\/td>Tiered royalties on net sales<\/td><\/tr>
IND Status<\/strong><\/td>IND clearance granted in 2023<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>ISM4808<\/th>Competitive Context<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Oral, small\u2011molecule PHD inhibitor<\/strong> (prolyl hydroxylase domain)<\/td>Modulates HIF pathway for anemia, ischemia, inflammatory diseases<\/td><\/tr>
Design<\/strong><\/td>AI\u2011empowered by Insilico\u2019s Chemistry42<\/strong> engine<\/td>Novel scaffold discovered via generative AI vs. traditional HTS<\/td><\/tr>
Selectivity<\/strong><\/td>Best\u2011in\u2011class potential<\/strong> (high PHD selectivity)<\/td>Differentiated from earlier pan\u2011PHD inhibitors (roxadustat, vadadustat)<\/td><\/tr>
Indications<\/strong><\/td>Undisclosed; likely anemia of chronic disease, ischemic conditions<\/strong><\/td>Expands PHD class beyond CKD anemia<\/td><\/tr>
Development Stage<\/strong><\/td>IND\u2011ready<\/strong> (clearance 2023)<\/td>Ready for Phase\u202f1 initiation in China H2\u202f2026<\/td><\/tr>
Route<\/strong><\/td>Oral (QD dosing)<\/td>Patient\u2011friendly vs. injectable biologics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n